Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884357 | 1.00 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884332 | 1.00 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884314 | 1.00 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884336 | 1.00 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884334 | 1.00 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL18025230 | 1.00 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL18591728 | 1.00 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL10177795 | 0.97 | HRH4 (0.37) | HRH4HRH3POLB | |
| SCHEMBL2600181 | 0.89 | HRH4 (0.34) | HRH4HRH3POLB | |
| SCHEMBL1276622 | 0.86 | HRH4 (0.45) | HRH4HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220124-A1 | NOVEL COMPOUNDS HAVING BET, ESTROGEN RECEPTOR, AND ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | HRH4 3892/4885HRH3 4322/4885POLB 1367/4885 |
| US-20220220124-A1 | NOVEL COMPOUNDS HAVING BET, ESTROGEN RECEPTOR, AND ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, ESRRA, ESR1 | HRH4 2555/4885HRH3 2396/4885POLB 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.